JOURNAL OF PSYCHOACTIVE DRUGS, published by Routledge Journals, Taylor & Francis Ltd, stands as a leading resource in the fields of psychology and medicine, focusing on the intersection of psychoactive substances and their impact on human behavior. With an ISSN of 0279-1072 and E-ISSN 2159-9777, this esteemed journal has been a pivotal platform for rigorous research since its inception in 1967, contributing to the understanding of drug use, its societal implications, and therapeutic potentials. It currently holds a Q2 ranking in both the miscellaneous categories of Medicine and Psychology for 2023, reflecting its significant standing within academic circles. Moreover, its Scopus rankings place it at the 49th percentile in General Psychology and 101st in Medicine, underscoring its relevance in contemporary research. Although it is not available via Open Access, the journal maintains a commitment to advancing knowledge through its annual publications until 2024. JOURNAL OF PSYCHOACTIVE DRUGS is essential for researchers, professionals, and students seeking to explore the complexities of psychoactive substances and their effects in various contexts.

ADDICTIVE BEHAVIORS is a prestigious journal published by PERGAMON-ELSEVIER SCIENCE LTD, specializing in the critical examination and exploration of addiction-related issues across diverse fields including Clinical Psychology, Psychiatry and Mental Health, and Toxicology. With a robust history dating back to 1975 and convergence extending to 2024, the journal is esteemed for its rigorous peer-reviewed research that contributes significantly to understanding addiction phenomena. Ranked in the Q1 category for its focus areas, it stands out within the academic community, evidenced by its impressive Scopus rankings—25th in Clinical Psychology and 14th in Toxicology—placing it in the top tier of its disciplines. This journal offers valuable insights into addiction behaviors, treatment methodologies, and public health implications, making it an essential resource for researchers, practitioners, and students seeking to advance their knowledge and impact the field. Although not Open Access, it provides vital access options for institutions and individuals invested in addiction studies.

Drug and Alcohol Dependence is a premier journal published by Elsevier Ireland Ltd, dedicated to the rigorous exploration and analysis of substance use disorders, including drug and alcohol dependencies. With its established history since 1975 and a remarkable convergence of research extending to 2024, the journal holds a prestigious position within the academic community, evidenced by its Q1 ranking in multiple categories, including Pharmacology, Psychiatry and Mental Health, and Toxicology for 2023. It ranks impressively among its peers, underscored by Scopus rankings of #46, #99, and #27 in key fields related to medical pharmacology and toxicology. As a non-open access title, it caters to a global readership of researchers, professionals, and students, providing them with peer-reviewed insights into critical developments and innovative methodologies in the field. The journal’s commitment to advancing knowledge and understanding of drug and alcohol dependence is essential for addressing the global challenges posed by substance use, making it a valuable resource for all stakeholders in public health and clinical practice.

PSYCHOLOGICAL MEDICINE is a leading journal in the field of psychiatry and psychology, published by Cambridge University Press. With its ISSN 0033-2917 and E-ISSN 1469-8978, this journal has firmly established itself as a premier platform for cutting-edge research since its inception in 1970. It consistently ranks in the top quartile for both Applied Psychology and Psychiatry and Mental Health, reflecting its exceptional impact in the field, with a 2023 Scopus ranking of #36 out of 567 in Psychiatry and Mental Health, and #21 out of 249 in Applied Psychology. The journal aims to publish comprehensive studies that explore the interplay between psychological phenomena and medical health, contributing vital insights that advance both theoretical understanding and clinical practice. Although it is not an Open Access journal, PSYCHOLOGICAL MEDICINE remains a vital resource for researchers, professionals, and students committed to the scientific investigation of mental health issues.

DRUG AND ALCOHOL REVIEW, published by Wiley, is a leading journal dedicated to advancing the scholarship in the fields of drug and alcohol research. Since its inception in 1989, this esteemed publication has provided a critical platform for the dissemination of innovative research findings, reviews, and theoretical papers, addressing pressing issues in substance use and addiction. With an impact factor that places it in the Q1 category in both Health (social science) and Medicine (miscellaneous), it ranks #78 out of 371 in the Scopus index for Health and #115 out of 398 in Medicine, reflecting its significant influence and high citation rates among scholars. The journal is committed to fostering a multidisciplinary approach, integrating perspectives from psychology, sociology, public health, and medicine, to inform policy and practice. Accessible to researchers and practitioners alike, *DRUG AND ALCOHOL REVIEW* serves as an essential resource for anyone invested in understanding and addressing the complexities of drug and alcohol use in society.

Preventive Medicine Reports is a premier open-access journal published by Elsevier, dedicated to advancing the field of preventive medicine and public health. With a focus on innovative research and practices since its inception in 2014, this journal has established itself in the top quartile (Q1) of both Health Informatics and Public Health, Environmental and Occupational Health categories as of 2023. This positions it among the leading publications in its field, showcasing significant contributions to health informatics and public health strategies. The journal's accessibility allows researchers, professionals, and students worldwide to engage with cutting-edge studies that inform health policy and preventive initiatives. By fostering an open exchange of knowledge, Preventive Medicine Reports aims to reduce health disparities and improve population health outcomes, making it an essential resource for anyone invested in the future of health sciences.

Adicciones is a prominent academic journal dedicated to the fields of Medicine and Psychiatry, focusing on the multi-faceted issues surrounding addiction and substance use. Published by SOCIDROGALCOHOL in Spain, this journal has been a critical resource for researchers, clinicians, and students since its inception in 1994, with a commitment to advancing knowledge in addiction science for the benefit of public health. With an impressive impact factor that places it in the Q3 category of both Medicine (Miscellaneous) and Psychiatry and Mental Health according to 2023 rankings, Adicciones is recognized for its high-quality peer-reviewed articles that contribute to the ongoing dialogue in these vital fields. Although not currently an open-access journal, it provides valuable subscription-based access to its extensive repository of research findings and reviews, fostering a deeper understanding of the complex dynamics of addiction. The journal's continued relevance is underscored by its convergence into 2024, promising ongoing contributions that inspire new ideas and practices to combat addiction.

DRUGS-EDUCATION PREVENTION AND POLICY is a premier scholarly journal published by Taylor & Francis Ltd, focusing on the critical intersection of drug education, prevention strategies, and policy formulation. Established in 1994 and continuing through its converged years into 2024, this journal holds significant relevance within the health and social sciences fields, with commendable standings reflected in its 2023 category quartile rankings of Q2 in both Health (Social Science) and Medicine (Miscellaneous). With an impact ranking that places it in the 73rd and 67th percentiles respectively, it serves as an influential platform for researchers, professionals, and students to disseminate innovative research, case studies, and policy analyses. Those interested in the complexities of drug-related issues are encouraged to explore the insights provided by this journal, contributing to the ongoing discourse in effective prevention and education practices in the context of drug use and its social implications. Although access to articles is not open, the wealth of knowledge presented is invaluable for academia and policy formulation alike.

Psychology & Health is a leading academic journal published by Taylor & Francis Ltd, dedicated to advancing the understanding of psychological influences on health and well-being. Since its inception in 1987, the journal has been pivotal in disseminating high-quality research, with a current ISSN of 0887-0446 and E-ISSN of 1476-8321. Recognized for its contributions to the field, it holds esteemed rankings, being classified in the Q2 quartile in Applied Psychology and Q1 quartile in Public Health (2023). With Scopus rankings placing it in the 87th percentile for Public Health and 80th in Applied Psychology, *Psychology & Health* provides researchers, professionals, and students with invaluable insights into the intersection of psychological research and health outcomes. The journal offers a rich platform for exploring contemporary issues and methodologies, encouraging submissions that advance the field and promote interdisciplinary dialogue. Although it is not an open-access journal, articles are available through institutional subscriptions, ensuring robust accessibility for the academic community.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, published by the American Psychological Association, stands as a pivotal resource within the fields of pharmacology and psychiatry. With an ISSN of 1064-1297 and an E-ISSN of 1936-2293, this journal contributes significantly to the understanding of psychopharmacological interventions through its rich array of research articles, reviews, and clinical studies. Classified within the Q2 category in both Pharmacology and Psychiatry and Mental Health, it reflects a solid standing in academic performance, evidenced by its rankings in Scopus, where it places within the top half of its categories. Spanning from 1993 to 2024, it seeks to provide an essential platform for the dissemination of knowledge and advancements that influence clinical practice and therapeutic approaches. Although not an open-access journal, its impact on the development of evidence-based psychopharmacological treatments cannot be overstated, making it a vital resource for researchers, clinically active professionals, and students eager to stay abreast of cutting-edge developments in mental health and pharmacology.